InnoCare Pharma Reports the IND Clearance of ICP-248 from the US FDA for Hematologic Malignancies
Shots:
- The US FDA grants clearance to the company’s IND application of ICP-248 to conduct a P-I trial for investigating the efficacy, safety, tolerability and PK of ICP-248 to treat hematologic malignancies
- The P-I dose escalation study evaluating ICP-248, ongoing across China, has revealed the drug’s favorable efficacy and safety profiles
- ICP-248 (oral) is an anti-tumor drug that restores the mechanism of programmed cell death by selectively inhibiting BCL2. It is being developed for the treatment of hematologic malignancies as monotx. or in combination with other therapies
Ref: Innocare | Image: Innocare
Related News:- Innocare Announces the Results of P-II Study for TYK2 Inhibitor ICP-332 in Patients with Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
